Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the closing of a multi-year licensing agreement with University Hospitals...
-
MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...
-
Orelabrutinib is a Phase 2 oral small molecule Bruton’s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrierInnoCare to receive a $125 million upfront...
-
TULSA, Okla., July 12, 2021 (GLOBE NEWSWIRE) -- OG DNA Genetics (“DNA” or the “Company”), a globally recognized leading cannabis brand, today announced a nursery licensing agreement (the “Nursery...
-
MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation...
-
SHANGHAI, China, July 09, 2021 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ: HTHT and HKEX: 1179) (“Huazhu” or “our”), a world-leading hotel group, announced that Steigenberger Hotels AG, a...
-
TORONTO, July 08, 2021 (GLOBE NEWSWIRE) -- Unigold Inc. (“Unigold” or the “Company”) (TSX-V:UGD, OTCQX:UGDIF, FSE:UGB1) is pleased to announce a non-brokered private placement of up to 23,076,923...
-
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
-
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...
-
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...